NZ514464A - Apomorphine and sildenafil composition - Google Patents

Apomorphine and sildenafil composition

Info

Publication number
NZ514464A
NZ514464A NZ514464A NZ51446400A NZ514464A NZ 514464 A NZ514464 A NZ 514464A NZ 514464 A NZ514464 A NZ 514464A NZ 51446400 A NZ51446400 A NZ 51446400A NZ 514464 A NZ514464 A NZ 514464A
Authority
NZ
New Zealand
Prior art keywords
apomorphine
sildenafil
administered
treatment
sildenafil composition
Prior art date
Application number
NZ514464A
Other languages
English (en)
Inventor
Ragab El-Rashidy
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of NZ514464A publication Critical patent/NZ514464A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ514464A 1999-03-16 2000-03-14 Apomorphine and sildenafil composition NZ514464A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/270,035 US6087362A (en) 1999-03-16 1999-03-16 Apomorphine and sildenafil composition
PCT/US2000/006654 WO2000054774A1 (fr) 1999-03-16 2000-03-14 Composition d'apomorphine et de sildenafil

Publications (1)

Publication Number Publication Date
NZ514464A true NZ514464A (en) 2004-01-30

Family

ID=23029614

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ514464A NZ514464A (en) 1999-03-16 2000-03-14 Apomorphine and sildenafil composition

Country Status (21)

Country Link
US (1) US6087362A (fr)
EP (1) EP1173178B1 (fr)
JP (1) JP2002539163A (fr)
CN (1) CN1350454A (fr)
AT (1) ATE302003T1 (fr)
AU (1) AU3744500A (fr)
BR (1) BR0009016A (fr)
CA (1) CA2367605A1 (fr)
CZ (1) CZ20013344A3 (fr)
DE (1) DE60022021T2 (fr)
DK (1) DK1173178T3 (fr)
ES (1) ES2244418T3 (fr)
HU (1) HUP0200549A3 (fr)
IL (1) IL145487A0 (fr)
MX (1) MXPA01009332A (fr)
NO (1) NO324511B1 (fr)
NZ (1) NZ514464A (fr)
PL (1) PL350313A1 (fr)
PT (1) PT1173178E (fr)
WO (1) WO2000054774A1 (fr)
ZA (1) ZA200107920B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
MXPA03001858A (es) * 2000-08-30 2004-05-21 Unimed Pharmaceuticals Inc Metodo para el tratamiento de la disfuncion erectil e incremento en el libido del hombre.
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
NZ527113A (en) * 2001-02-08 2005-04-29 Pharmacia Corp Rapid-onset medicament for the treatment of sexual dysfunction
ES2180446B1 (es) * 2001-07-02 2004-01-16 Esteve Labor Dr Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AR036674A1 (es) * 2001-08-28 2004-09-29 Schering Corp Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
US20060004190A1 (en) * 2002-03-19 2006-01-05 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7037257B1 (en) * 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
TWI330529B (en) * 2003-01-13 2010-09-21 Horphag Res Luxembourg Holding Sa A preparation for improving sperm quality or fertility,a kit comprising the same and uses thereof
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) * 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
KR101292492B1 (ko) * 2004-05-11 2013-08-01 이모셔널 브레인 비.브이. 약제학적 제형물 및 여성 성기능 부전의 치료에서 그것의용도
CN102406650A (zh) * 2004-10-20 2012-04-11 恩多研究公司 单独的性甾体前体或与选择性雌激素受体调节剂联合用于防治绝经后女性的阴道疾病和病症
PT1937276E (pt) 2005-10-12 2013-02-21 Besins Healthcare Luxembourg Gel de testosterona melhorado e método para a sua utilização
CN101674728A (zh) * 2007-02-12 2010-03-17 Dmi生物科学公司 降低曲马多的副作用
KR20150089085A (ko) * 2007-02-12 2015-08-04 브릭스 파마슈티컬스 인코퍼레이티드 조루 및 발기부전을 동시에 치료하는 방법
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
DK2238168T3 (da) * 2007-12-26 2014-08-25 Biotest Ag Midler, der er målrettet mod cd138 og anvendelser deraf
RU2486203C2 (ru) * 2007-12-26 2013-06-27 Биотест Аг Способы улучшения направленного воздействия на cd138-экспрессирующие опухолевые клетки и агенты для их осуществления
EP2238169A1 (fr) * 2007-12-26 2010-10-13 Biotest AG Procédé permettant de réduire les effets secondaires cytotoxiques et d'améliorer l'efficacité des immunoconjugués
AU2008339911B2 (en) * 2007-12-26 2014-02-27 Biotest Ag Immunoconjugates targeting CD138 and uses thereof
US20090246298A1 (en) * 2008-03-31 2009-10-01 Ceola P. Steele Viagra
US20100184722A1 (en) * 2008-12-19 2010-07-22 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
WO2010128087A2 (fr) * 2009-05-06 2010-11-11 Biotest Ag Utilisations d'immunoconjugués ciblant l'antigène cd138
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
AU2010259971C1 (en) 2009-06-12 2017-02-16 Sunovion Pharmaceuticals Inc. Sublingual apomorphine
WO2012000634A1 (fr) 2010-06-29 2012-01-05 Georg Bambach Composition pharmaceutique pour le traitement de dysfonction érectile
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
CN103476372B (zh) 2010-12-16 2016-04-27 Cynapsus疗法有限公司 舌下薄膜
BR112014013694A2 (pt) 2011-12-08 2017-06-13 Biotest Ag método para tratar uma doença, e, kit
EP3285771A4 (fr) 2015-04-21 2018-12-05 Sunovion Pharmaceuticals Inc. Méthodes de traitement de la maladie de parkinson par l'administration d'apomorphine à une muqueuse orale
WO2017168174A1 (fr) 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
DK0758895T3 (da) * 1994-04-22 2000-06-13 Pentech Pharmaceuticals Inc Sublinguale dosisformer indeholdende apomorphin til anvendelse ved behandling af erektil dysfunktion
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
ES2270517T3 (es) * 1997-05-19 2007-04-01 Zonagen, Inc. Terapia de combinacion para modular la respuesta sexual humana.
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction

Also Published As

Publication number Publication date
CN1350454A (zh) 2002-05-22
DE60022021T2 (de) 2006-06-08
PL350313A1 (en) 2002-12-02
ZA200107920B (en) 2003-03-26
US6087362A (en) 2000-07-11
EP1173178A1 (fr) 2002-01-23
MXPA01009332A (es) 2002-06-21
IL145487A0 (en) 2002-06-30
CZ20013344A3 (cs) 2002-08-14
ATE302003T1 (de) 2005-09-15
HUP0200549A3 (en) 2004-07-28
DE60022021D1 (de) 2005-09-22
CA2367605A1 (fr) 2000-09-21
ES2244418T3 (es) 2005-12-16
PT1173178E (pt) 2005-11-30
HUP0200549A2 (hu) 2002-07-29
JP2002539163A (ja) 2002-11-19
DK1173178T3 (da) 2005-11-07
AU3744500A (en) 2000-10-04
BR0009016A (pt) 2002-04-16
NO20014519L (no) 2001-10-25
NO324511B1 (no) 2007-11-05
NO20014519D0 (no) 2001-09-17
EP1173178A4 (fr) 2002-09-04
WO2000054774A1 (fr) 2000-09-21
EP1173178B1 (fr) 2005-08-17

Similar Documents

Publication Publication Date Title
PL350313A1 (en) Apomorphine and sildenafil composition
NZ540385A (en) Use of 1-oxo-2-(2, 6-dioxopiperidin-3-yl)-4-methylisoindoline in the manufacture of a medicamnent for treatment of brain cancer
HK1177901A1 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin 10--10- t
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
CA2582452A1 (fr) Doxorubicine liposomale pegylee en combinaison avec l'ecteinascidine 743
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
CA2368614A1 (fr) Traitement du cancer ameliore avec le temozolomide
JP2002540148A5 (fr)
FI20011464A0 (fi) Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
CA2516458A1 (fr) Utilisation de composes de kahalalide pour la fabrication d'un medicament pour le traitement de psoriasis
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
PT1265629E (pt) Utilizacao da hormona de crescimento em dose baixa
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
BRPI0503488A (pt) agente de tratamento para sìndrome de intestino irritável com diarréia predominante

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)